Neuropsychiatric Disorders and Amyotrophic Lateral Sclerosis

What neuropsychiatric conditions are relatives of people with ALS at risk for? Are other genes involved besides C9orf72?

Related Videos
Related Content

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

March 25th 2023

Special Episode: Trofinetide Approved for Rett Syndrome

March 13th 2023

Losmapimod Demonstrates Significant Slowing of Facioscapulohumeral Muscular Dystrophy Over Long-Term Period

March 23rd 2023

Episode 80: Advancing Treatment for Rare Neuromuscular Disorders

January 13th 2023

Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMD

March 23rd 2023

FDA AdComm on Tofersen Supports NfL as Surrogate End Point of Clinical Benefit, But Is It Enough for Approval?

March 22nd 2023

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

March 25th 2023

Special Episode: Trofinetide Approved for Rett Syndrome

March 13th 2023

Losmapimod Demonstrates Significant Slowing of Facioscapulohumeral Muscular Dystrophy Over Long-Term Period

March 23rd 2023

Episode 80: Advancing Treatment for Rare Neuromuscular Disorders

January 13th 2023

Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMD

March 23rd 2023

FDA AdComm on Tofersen Supports NfL as Surrogate End Point of Clinical Benefit, But Is It Enough for Approval?

March 22nd 2023

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

March 25th 2023

Special Episode: Trofinetide Approved for Rett Syndrome

March 13th 2023

Losmapimod Demonstrates Significant Slowing of Facioscapulohumeral Muscular Dystrophy Over Long-Term Period

March 23rd 2023

Episode 80: Advancing Treatment for Rare Neuromuscular Disorders

January 13th 2023

Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMD

March 23rd 2023

FDA AdComm on Tofersen Supports NfL as Surrogate End Point of Clinical Benefit, But Is It Enough for Approval?

March 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.